To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05376800
Title A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Boehringer Ingelheim
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | ESP | BEL

Facility Status City State Zip Country Details
Mayo Clinic-Arizona Phoenix Arizona 85054 United States Details
Yale New Haven Hospital New Haven Connecticut 06510 United States Details
Mayo Clinic Cancer Center Jacksonville Florida 32224 United States Details
Mayo Clinic, Rochester Rochester Minnesota 55905 United States Details
UZ Leuven Leuven 3000 Belgium Details
Hospital del Mar Barcelona 08003 Spain Details
Hospital Universitario 12 de Octubre Madrid 28041 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field